BRIEF-Agenus to start the phase 1/2 clinical trial of anti-OX40 By: Reuters: Company News November 30, 2016 at 09:25 AM EST * Agenus announces commencement of phase 1/2 clinical trial of anti-OX40 checkpoint antibody INCAGN1949 in patients with solid tumors Read More >> Related Stocks: Agenus Inc Incyte Corp